PMID- 21651449
OWN - NLM
STAT- MEDLINE
DCOM- 20110928
LR  - 20151119
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 10
DP  - 2011 Jul
TI  - Sitagliptin: a review.
PG  - 1613-22
LID - 10.1517/14656566.2011.580738 [doi]
AB  - INTRODUCTION: The ever-increasing burden of type 2 diabetes mellitus (T2DM) and 
      inadequate control in the majority of patients has led to a quest for newer 
      therapeutic options. There have been recent exciting advances in the treatment of 
      T2DM, targeting the enteroinsular axis with incretin-based therapies that include 
      the dipeptidyl peptidase IV (DPP-IV) inhibitors. AREAS COVERED: The background, 
      pharmacodynamic and pharmacokinetic profile of sitagliptin and important clinical 
      trials with this drug are discussed in this paper. This review is intended to 
      provide a comprehensive overview of the DPP-IV inhibitor sitagliptin, its 
      clinical use and an expert opinion about its place in the treatment algorithm of 
      diabetes management. EXPERT OPINION: Sitagliptin is a well-tolerated, moderately 
      efficacious, weight-neutral oral antidiabetic agent, with a low incidence of 
      hypoglycemia. It may have a particular role in the management of diabetic 
      patients with kidney or liver dysfunction. Animal studies indicate a protective 
      effect on the pancreatic beta cell, thus limiting the progression of the disease, 
      but this remains to be proven in humans.
CI  - (c) 2011 Informa UK, Ltd.
FAU - Subbarayan, Sreevidya
AU  - Subbarayan S
AD  - Cleveland Clinic, Cleveland, Ohio, 44195, USA.
FAU - Kipnes, Mark
AU  - Kipnes M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Administration, Oral
MH  - Algorithms
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects/pharmacology/therapeutic use
MH  - Pyrazines/adverse effects/pharmacology/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Triazoles/adverse effects/pharmacology/*therapeutic use
EDAT- 2011/06/10 06:00
MHDA- 2011/09/29 06:00
CRDT- 2011/06/10 06:00
PHST- 2011/06/10 06:00 [entrez]
PHST- 2011/06/10 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
AID - 10.1517/14656566.2011.580738 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Jul;12(10):1613-22. doi: 
      10.1517/14656566.2011.580738.